Eqis Capital Management, Inc. Cytokinetics Inc Transaction History
Eqis Capital Management, Inc.
- $1.19 Billion
- Q1 2024
A detailed history of Eqis Capital Management, Inc. transactions in Cytokinetics Inc stock. As of the latest transaction made, Eqis Capital Management, Inc. holds 2,963 shares of CYTK stock, worth $164,476. This represents 0.02% of its overall portfolio holdings.
Number of Shares
2,963Holding current value
$164,476% of portfolio
0.02%Shares
4 transactions
Others Institutions Holding CYTK
# of Institutions
458Shares Held
108MCall Options Held
7.2MPut Options Held
6.2M-
Black Rock Inc. New York, NY12.4MShares$689 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$555 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.12MShares$284 Million0.22% of portfolio
-
Bank Of America Corp Charlotte, NC4.78MShares$265 Million0.03% of portfolio
-
State Street Corp Boston, MA4.52MShares$251 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.23B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...